Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 3
2005 3
2006 7
2007 4
2008 6
2009 8
2010 9
2011 8
2012 9
2013 8
2014 9
2015 5
2016 7
2017 9
2018 10
2019 9
2020 17
2021 10
2022 8
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. Kalinsky K, et al. Among authors: o regan r. J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19. J Clin Oncol. 2023. PMID: 37207300 Clinical Trial.
Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Gradishar WJ, et al. Among authors: o regan r. Future Oncol. 2023 May;19(16):1099-1112. doi: 10.2217/fon-2022-1040. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170847 Free article. Review.
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
Taylor C, Meisel J, Foreman AJ, Russell C, Bandyopadhyay D, Deng X, Floyd L, Zelnak A, Bear H, O'Regan R. Taylor C, et al. Among authors: o regan r. Breast Cancer Res Treat. 2023 May;199(1):91-98. doi: 10.1007/s10549-023-06890-7. Epub 2023 Mar 10. Breast Cancer Res Treat. 2023. PMID: 36897465 Free PMC article. Clinical Trial.
144 results